Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Makers Rush to Apply for Anthrax as Additional Indication
November 19, 2001
- BI's Equity Stake in SSP exceeds 50%
November 12, 2001
- NEW PRODUCTS NEWS IN BRIEF
November 12, 2001
- Similar Function Comparison Method for Medical Materials Proposed
November 12, 2001
- AstraZeneca to Increase Share in Japan to 1.7% at End of 2001: CE McKillop
November 12, 2001
- Terumo Licenses New APD System from Debiotech of Spain
November 12, 2001
- BUSINESS NEWS IN BRIEF
November 12, 2001
- GL for Global Drug Development Needed: JPMA Expert
November 12, 2001
- Makers Providing More Products in Small Packages: Yano Report
November 12, 2001
- Approval Process for Medical Devices to Be Reviewed
November 12, 2001
- Sankyo Receives Approvable Letter for CS-866 from US FDA
November 12, 2001
- Fresenius: New APD System "sleep・safe"
November 12, 2001
- Sumitomo's Half-year Sales Top \69.2 Bil., Up \9 Bil.: President Yokotsuka
November 12, 2001
- GEMS Targeting Double-Digit Growth in Japanese Market: President Hogan
November 12, 2001
- EFPIA-EBC Position Statement: Japan（2）
November 12, 2001
- JACDS to Hold Self-medication Summit
November 12, 2001
- EFPIA-EBC Position Statement: Japan（1）
November 12, 2001
- Comprehensive Research Necessary in Psychiatry: Seminar
November 12, 2001
- ARB Effective for Heart Failure: Novartis Lecture
November 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 12, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…